These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 33535955)

  • 1. MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types.
    Bacolod MD; Barany F
    Curr Cancer Drug Targets; 2021; 21(4):360-374. PubMed ID: 33535955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous methylation of the O(6)-methylguanine-DNA methyltransferase promoter in immortalized IMR90 cell lines.
    Danam RP; Howell SR; Remack JS; Brent TP
    Int J Oncol; 2001 Jun; 18(6):1187-93. PubMed ID: 11351250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
    Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
    Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
    Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
    BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
    Zapanta Rinonos S; Li T; Pianka ST; Prins TJ; Eldred BSC; Kevan BM; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
    J Neurooncol; 2024 Jan; 166(1):129-142. PubMed ID: 38224404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
    Moen EL; Stark AL; Zhang W; Dolan ME; Godley LA
    Mol Cancer Ther; 2014 May; 13(5):1334-44. PubMed ID: 24568970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer.
    Nakagawachi T; Soejima H; Urano T; Zhao W; Higashimoto K; Satoh Y; Matsukura S; Kudo S; Kitajima Y; Harada H; Furukawa K; Matsuzaki H; Emi M; Nakabeppu Y; Miyazaki K; Sekiguchi M; Mukai T
    Oncogene; 2003 Dec; 22(55):8835-44. PubMed ID: 14647440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
    BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Esteller M; Garcia-Foncillas J; Andion E; Goodman SN; Hidalgo OF; Vanaclocha V; Baylin SB; Herman JG
    N Engl J Med; 2000 Nov; 343(19):1350-4. PubMed ID: 11070098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
    Hegi ME; Liu L; Herman JG; Stupp R; Wick W; Weller M; Mehta MP; Gilbert MR
    J Clin Oncol; 2008 Sep; 26(25):4189-99. PubMed ID: 18757334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
    Jiang G; Jiang AJ; Xin Y; Li LT; Cheng Q; Zheng JN
    Mol Biol Rep; 2014 Oct; 41(10):6659-65. PubMed ID: 24990698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins.
    Danam RP; Howell SR; Brent TP; Harris LC
    Mol Cancer Ther; 2005 Jan; 4(1):61-9. PubMed ID: 15657354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
    van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P
    Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.